Journal of Microbiology and Biotechnology

  • 제34권4호
  • /
  • Pages.765-773
  • /
  • 2024
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지
DOI QR코드

DOI QR Code

Ozonated Sunflower Oil (OSO) Alleviates Inflammatory Responses in Oxazolone-Induced Atopic Dermatitis (AD)-Like Mice and LPS- Treated RAW 264.7 Cells

  • Su-Young Kim (Department of Dermatology, College of Medicine, Chung-Ang University) ;
  • Jung Ok Lee (Department of Dermatology, College of Medicine, Chung-Ang University) ;
  • Sue Lee (Department of Dermatology, College of Medicine, Chung-Ang University) ;
  • Jihye Heo (Department of Dermatology, College of Medicine, Chung-Ang University) ;
  • Kyung-Hyun Cho (Raydel Research Institute, Medical Innovation Complex) ;
  • Ashutosh Bahuguna (Raydel Research Institute, Medical Innovation Complex) ;
  • Kwang-Ho Yoo (Department of Dermatology, College of Medicine, Chung-Ang University) ;
  • Beom Joon Kim (Department of Dermatology, College of Medicine, Chung-Ang University)
  • 투고 : 2023.10.25
  • 심사 : 2024.01.03
  • 발행 : 2024.04.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Ozone, a highly reactive oxidant molecule, is widely used as a complementary therapy for various skin diseases, including wound healing, pressure ulcers, diabetic foot, and infections. However, there is limited research on the effectiveness of ozone for atopic dermatitis (AD). Ozonated sunflower oil (OSO) is an active ingredient obtained from partially ozonated sunflower oil (SO). OSO markedly reduced the LPS-induced increase in IL-1β and nitric oxide (NO) levels in RAW 264.7 mouse macrophage cells. Oxazolone (OXZ) was applied to hairless mice to induce AD-like skin symptoms and immune response. OSO significantly alleviated the OXZ-induced increases in the number of infiltrating mast cells, epidermal thickness, AD symptoms, thymic stromal lymphopoietin (TSLP), and filaggrin, as well as the serum levels of NO, IgE, IL-1β, and TNF-α. Furthermore, OSO inhibited the IL-4/STAT3/MAPK pathway and the expression of NF-κB. Our results suggest that OSO treatment could relieve AD-mediated skin damage through its anti-inflammatory and antioxidant activities. Therefore, it can be used as a therapeutic agent against AD-related skin diseases.

키워드

참고문헌

  1. Lee HJ, Lee SH. 2014. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol. Res. 6: 276-287.  https://doi.org/10.4168/aair.2014.6.4.276
  2. Murota H, Koike Y, Morisaki H, Matsumoto M, Takenaka M. 2022. Exacerbating factors and disease burden in patients with atopic dermatitis. Allergol. Int. 71: 25-30.  https://doi.org/10.1016/j.alit.2021.10.002
  3. Bylund S, Kobyletzki LB, Svalstedt M, Svensson A. 2020. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm. Venereol. 100: adv00160. 
  4. Luger T, Amagai M, Dreno B, Dagnelie MA, Liao W, Kabashima K, et al. 2021. Atopic dermatitis: role of the skin barrier, environment, microbiome, and therapeutic agents. J. Dermatol. Sci. 102: 142-157.  https://doi.org/10.1016/j.jdermsci.2021.04.007
  5. Chovatiya R, Silverberg JI. 2022. DESCRIBE-AD: a novel classification framework for atopic dermatitis. J. Am. Acad. Dermatol. 87: 541-550.  https://doi.org/10.1016/j.jaad.2021.10.058
  6. Ingrid Bohm, Bauer R. 1997. Th1-Zellen, Th2-Zellen und atopische dermatitis. Hautarzt 48: 223-227.  https://doi.org/10.1007/s001050050573
  7. Kim YJ, Choi MJ, Bak DH, Lee BC, Ko EJ, Ahn GR, et al. 2018. Topical administration of EGF suppresses immune response and protects skin barrier in DNCB-induced atopic dermatitis in NC/Nga mice. Sci. Rep. 8: 11895. 
  8. Leung DYM. 1999. Pathogenesis of atopic dermatitis. J. Allergy Clin. Immunol. 104. 
  9. A Wollenberg, S Barbarot, T Bieber, S Christen-Zaech, M Deleuran, A Fink-Wagner, et al. 2018. Consensus-based European guidelines for treatment ofatopic eczema (atopic dermatitis) in adults and children:part I. JEADV 32: 657-682.  https://doi.org/10.1111/jdv.14891
  10. Ferreira S, Guttman-Yassky E, Torres T. 2020. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am. J. Clin. Dermatol. 21: 783-798.  https://doi.org/10.1007/s40257-020-00548-6
  11. Simon D, Bieber T. 2014. Systemic therapy for atopic dermatitis. Allergy 69: 46-55.  https://doi.org/10.1111/all.12339
  12. Kim BE, Leung DYM. 2018. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol. Res. 10: 207-215.  https://doi.org/10.4168/aair.2018.10.3.207
  13. Drislane C, Irvine AD. 2020. The role of filaggrin in atopic dermatitis and allergic disease. Ann. Allergy Asthma Immunol. 124: 36-43.  https://doi.org/10.1016/j.anai.2019.10.008
  14. Osawa R, Akiyama M, Shimizu H. 2011. Filaggrin gene defects and the risk of developing allergic disorders. Allergol. Int. 60: 1-9.  https://doi.org/10.2332/allergolint.10-RAI-0270
  15. Zaniboni MC, Samorano LP, Orfali RL, Aoki V. 2016. Skin barrier in atopic dermatitis: beyond filaggrin. An. Bras. Dermatol. 91: 472-478.  https://doi.org/10.1590/abd1806-4841.20164412
  16. Kim JH, Bae HC, Ko NY, Lee SH, Jeong SH, Lee H, et al. 2015. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J. Allergy Clin. Immunol. 136: 205-208 e209. 
  17. Liu L, Zeng L, Gao L, Zeng J, Lu J. 2023. Ozone therapy for skin diseases: cellular and molecular mechanisms. Int. Wound J. 20: 2376-2385.  https://doi.org/10.1111/iwj.14060
  18. Di Mauro R, Cantarella G, Bernardini R, Di Rosa M, Barbagallo I, Distefano A, et al. 2019. The biochemical and pharmacological properties of ozone: the smell of protection in acute and chronic diseases. Int. J. Mol. Sci. 20: 634. 
  19. Wen Q, Liu D, Wang X, Zhang Y, Fang S, Qiu X, et al. 2022. A systematic review of ozone therapy for treating chronically refractory wounds and ulcers. Int. Wound J. 19: 853-870.  https://doi.org/10.1111/iwj.13687
  20. Zeng J, Dou J, Gao L, Xiang Y, Huang J, Ding S, et al. 2020. Topical ozone therapy restores microbiome diversity in atopic dermatitis. Int. Immunopharmacol. 80: 106191. 
  21. Zeng J, Lei L, Zeng Q, Yao Y, Wu Y, Li Q, et al. 2020. Ozone therapy attenuates NF-kappaB-mediated local inflammatory response and activation of Th17 cells in treatment for psoriasis. Int. J. Biol. Sci. 16: 1833-1845.  https://doi.org/10.7150/ijbs.41940
  22. Raghad Abdulsalam Khaleel, Munaf Hashim Zalzala, Wrood Salim Al-khfajy, Yasir Wael Rashid, Mohammad A. 2022. POSSIBLE PROTECTIVE EFFECT OF OZONE THERAPY IN IMIQUIMOD INDUCED PSORIASIS-LIKE INFLAMMATION IN MICE. HIV Nursing 22: 809-813. 
  23. Cho KH, Kang DJ, Nam HS, Kim JH, Kim SY, Lee JO, et al. 2021. Ozonated sunflower oil exerted protective effect for embryo and cell survival via potent reduction power and antioxidant activity in HDL with strong antimicrobial activity. Antioxidants (Basel) 10: 1651. 
  24. Menendez S, Falcon L, Maqueira Y. 2011. Therapeutic efficacy of topical OLEOZON(R) in patients suffering from onychomycosis. Mycoses 54: e272-277.  https://doi.org/10.1111/j.1439-0507.2010.01898.x
  25. Man MQ, Hatano Y, Lee SH, Man M, Chang S, Feingold KR, et al. 2008. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J. Invest. Dermatol. 128: 79-86.  https://doi.org/10.1038/sj.jid.5701011
  26. Sharma JN, Al-Omran A, Parvathy SS. 2007. Role of nitric oxide in inflammatory diseases. Inflammopharmacology 15: 252-259.  https://doi.org/10.1007/s10787-007-0013-x
  27. Lopez-Castejon G, Brough D. 2011. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 22: 189-195.  https://doi.org/10.1016/j.cytogfr.2011.10.001
  28. Nathan C. 1992. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6: 3051-3064.  https://doi.org/10.1096/fasebj.6.12.1381691
  29. Angelika Bierhaus, Stephan Schiekofer, Markus Schwaninger, Martin Andrassy, Per M. Humpert, Jiang Chen, et al. 2001. Diabetes-associated sustained activation of the transcription factor nuclear factor-B. Diabetes 50: 2792-2808.  https://doi.org/10.2337/diabetes.50.12.2792
  30. Yoshiyuki Hattori , Sachiko Hattori, Noriyuki Sato, Kasai K. 2000. High-glucose-induced nuclear factor kB activation in vascular smooth muscle cells. Cardiovasc. Res. 46: 188-197.  https://doi.org/10.1016/S0008-6363(99)00425-3
  31. Ogawa T, Ishitsuka Y, Nakamura Y, Kubota N, Saito A, Fujisawa Y, et al. 2020. NRF2 Augments epidermal antioxidant defenses and promotes atopy. J. Immunol. 205: 907-914.  https://doi.org/10.4049/jimmunol.2000274
  32. Nakashima C, Yanagihara S, Otsuka A. 2022. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol. Int. 71: 40-46.  https://doi.org/10.1016/j.alit.2021.10.004
  33. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. 2002. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3: 673-680.  https://doi.org/10.1038/ni805
  34. Sano Y, Masuda K, Tamagawa-Mineoka R, Matsunaka H, Murakami Y, Yamashita R, et al. 2013. Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis. Clin. Exp. Immunol. 171: 330-337.  https://doi.org/10.1111/cei.12021
  35. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. 2017. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77: 521-546.  https://doi.org/10.1007/s40265-017-0701-9
  36. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. 2008. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol. Ther. 120: 172-185.  https://doi.org/10.1016/j.pharmthera.2008.08.002
  37. Bao L, Shi VY, Chan LS. 2012. IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: implication for atopic dermatitis. Mol. Immunol. 50: 91-97.  https://doi.org/10.1016/j.molimm.2011.12.008
  38. Furue M. 2020. Regulation of skin barrier function via competition between AHR axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. J. Clin. Med. 9: 3741. 
  39. Dai X, Muto J, Shiraishi K, Utsunomiya R, Mori H, Murakami M, et al. 2022. TSLP Impairs epidermal barrier integrity by stimulating the formation of nuclear IL-33/phosphorylated STAT3 complex in human keratinocytes. J. Investig. Dermatol. 142: 2100-2108.e2105.  https://doi.org/10.1016/j.jid.2022.01.005
  40. Sies H, Berndt C, Jones DP. 2017. Oxidative stress. Annu. Rev. Biochem. 86: 715-748.  https://doi.org/10.1146/annurev-biochem-061516-045037
  41. Longjam Shantabi, Ganesh Chandra Jagetia, M.Ayub Ali, Thaodem Tomcha Singh, Devi SV. 2014. Antioxidant properties of croton caudatus leaf extract in vitro. Transl. Med. Biotech. 2. 
  42. Rotti RB, Sunitha DV, Manjunath R, Roy A, Mayegowda SB, Gnanaprakash AP, et al. 2023. Green synthesis of MgO nanoparticles and its antibacterial properties. Front. Chem. 11: 1143614. 
  43. Ji H, Li XK. 2016. Oxidative stress in atopic dermatitis. Oxid. Med. Cell. Longev. 2016: 2721469. 
  44. Scassellati C, Ciani M, Galoforo AC, Zanardini R, Bonvicini C, Geroldi C. 2020. Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment. Mech. Ageing Dev. 186: 111210. 
  45. Wang Y, Che M, Xin J, Zheng Z, Li J, Zhang S. 2020. The role of IL-1beta and TNF-alpha in intervertebral disc degeneration. Biomed. Pharmacother. 131: 110660. 
  46. Schafer M, Dutsch S, auf dem Keller U, Navid F, Schwarz A, Johnson DA, et al. 2010. Nrf2 establishes a glutathione-mediated gradient of UVB cytoprotection in the epidermis. Genes Dev. 24: 1045-1058.  https://doi.org/10.1101/gad.568810
  47. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. 2018. Atopic dermatitis. Nat. Rev. Dis. Primers 4: 1.